Market Cap 3.06B
Revenue (ttm) 47.07M
Net Income (ttm) -223.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475.59%
Debt to Equity Ratio 0.00
Volume 470,100
Avg Vol 936,600
Day's Range N/A - N/A
Shares Out 65.12M
Stochastic %K 56%
Beta 2.07
Analysts Strong Sell
Price Target $61.95

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 5300
Address:
500 North Beacon Street, 4th Floor, Watertown, United States
swingingtech
swingingtech Jun. 10 at 12:37 PM
$TMSL $CNTA $KYMR $PRIM https://wallstreetwaves.com/we-did-the-math-tmsl-can-go-to-38/
0 · Reply
YasirTrades
YasirTrades Jun. 8 at 8:29 PM
GLMD setup looks like $ONC (+40%), $KYMR (+50%), $MLTX (+16% on takeover buzz), and $BPMC (+26% on $9B buyout). GLMD still under $1.40, $12+ book, low float, no dilution. Chart’s coiled. One spark and this can rip. GLMD #biotech #smallcaps #squeeze
0 · Reply
YasirTrades
YasirTrades Jun. 8 at 8:25 PM
GLMD setup reminds me of $KYMR (+41% on trial data), $MLTX (+20% on takeover buzz), $BPMC (+26% on $9B buyout), and $CRBU (+13% on volume/trial updates). $ is under $1.40 with $12+ book, low float, no dilution. Just needs a catalyst. GLMD #biotech #smallcaps
0 · Reply
QuiverQuant
QuiverQuant Jun. 6 at 2:51 PM
New Analyst Forecast: $KYMR Given 'Buy' Rating Read more on $KYMR: https://www.quiverquant.com/news/New+Analyst+Forecast%3A+%24KYMR+Given+%27Buy%27+Rating
1 · Reply
MaverikIT
MaverikIT Jun. 6 at 1:43 PM
$TGTX - welcome back to 40'$ - LFG $AXSM $KYMR
0 · Reply
MaverikIT
MaverikIT Jun. 5 at 3:54 PM
0 · Reply
Dkll303
Dkll303 Jun. 5 at 1:03 PM
$ASML $KYMR $PINS Been to $60, only on a road show for an offering for cash
0 · Reply
Tokenist
Tokenist Jun. 4 at 12:39 PM
📊 Analyst Action Alert: 2 Upgrades & 1 Downgrade You Should Know 💥 $KYMR is on fire—+64% in a week after KT-621 crushed trial expectations with over 90% STAT6 degradation. B.Riley upped it to Buy ($60 target), Morgan Stanley went Overweight with a juicy $79 target. Current price: $43.58. Eyes on $97 ceiling 👀 📈 $PINS just got a glow-up from JPM, now Overweight with a $40 PT. MAUs hit 570M, revenue +16% YoY, and shopping + ads = one resilient platform. Current: $33.13. Bullish? 32 analysts say yes. ⚠️ $ASML got hit with a downgrade from Barclays (Overweight ➝ Equal Weight) as U.S.-China trade tension drags it down. Still, avg PT sits at $857 vs. $747 now, with a ceiling at $1,104. AI still needs their EUV machines—dip = watchlist. Who's next to pop or drop? 💣
1 · Reply
Wrangler4
Wrangler4 Jun. 4 at 11:15 AM
$CADL WOW WOW , 2800 dollars spent on a “ superb “ drug for prostrate, lol !! PM Where MILLIONS are being spent at $KYMR PM to own a PHASE 1 company , hahaha, no Phase 2 or 3 GUESS TAK has credibility issues !!! And gets only 2800 out of the MILLIONS , Funds are spending ..BUT NOT ON HIM !!!! Hahah
0 · Reply
TalkMarkets
TalkMarkets Jun. 4 at 8:40 AM
Analyst Moves: 2 Upgrades And 1 Neutral Rating $PINS $KYMR $ASML https://talkmarkets.com/content/stocks--equities/analyst-moves-2-upgrades-and-1-neutral-rating?post=501170&userid=166882
0 · Reply
Latest News on KYMR
Kymera: Protein Degradation Could Drive Dupixent-Like Value

Dec 7, 2024, 1:07 AM EST - 6 months ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value


Kymera Therapeutics Announces Proposed Public Offering

Aug 19, 2024, 4:01 PM EDT - 10 months ago

Kymera Therapeutics Announces Proposed Public Offering


Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:23 AM EDT - 11 months ago

Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript


swingingtech
swingingtech Jun. 10 at 12:37 PM
$TMSL $CNTA $KYMR $PRIM https://wallstreetwaves.com/we-did-the-math-tmsl-can-go-to-38/
0 · Reply
YasirTrades
YasirTrades Jun. 8 at 8:29 PM
GLMD setup looks like $ONC (+40%), $KYMR (+50%), $MLTX (+16% on takeover buzz), and $BPMC (+26% on $9B buyout). GLMD still under $1.40, $12+ book, low float, no dilution. Chart’s coiled. One spark and this can rip. GLMD #biotech #smallcaps #squeeze
0 · Reply
YasirTrades
YasirTrades Jun. 8 at 8:25 PM
GLMD setup reminds me of $KYMR (+41% on trial data), $MLTX (+20% on takeover buzz), $BPMC (+26% on $9B buyout), and $CRBU (+13% on volume/trial updates). $ is under $1.40 with $12+ book, low float, no dilution. Just needs a catalyst. GLMD #biotech #smallcaps
0 · Reply
QuiverQuant
QuiverQuant Jun. 6 at 2:51 PM
New Analyst Forecast: $KYMR Given 'Buy' Rating Read more on $KYMR: https://www.quiverquant.com/news/New+Analyst+Forecast%3A+%24KYMR+Given+%27Buy%27+Rating
1 · Reply
MaverikIT
MaverikIT Jun. 6 at 1:43 PM
$TGTX - welcome back to 40'$ - LFG $AXSM $KYMR
0 · Reply
MaverikIT
MaverikIT Jun. 5 at 3:54 PM
0 · Reply
Dkll303
Dkll303 Jun. 5 at 1:03 PM
$ASML $KYMR $PINS Been to $60, only on a road show for an offering for cash
0 · Reply
Tokenist
Tokenist Jun. 4 at 12:39 PM
📊 Analyst Action Alert: 2 Upgrades & 1 Downgrade You Should Know 💥 $KYMR is on fire—+64% in a week after KT-621 crushed trial expectations with over 90% STAT6 degradation. B.Riley upped it to Buy ($60 target), Morgan Stanley went Overweight with a juicy $79 target. Current price: $43.58. Eyes on $97 ceiling 👀 📈 $PINS just got a glow-up from JPM, now Overweight with a $40 PT. MAUs hit 570M, revenue +16% YoY, and shopping + ads = one resilient platform. Current: $33.13. Bullish? 32 analysts say yes. ⚠️ $ASML got hit with a downgrade from Barclays (Overweight ➝ Equal Weight) as U.S.-China trade tension drags it down. Still, avg PT sits at $857 vs. $747 now, with a ceiling at $1,104. AI still needs their EUV machines—dip = watchlist. Who's next to pop or drop? 💣
1 · Reply
Wrangler4
Wrangler4 Jun. 4 at 11:15 AM
$CADL WOW WOW , 2800 dollars spent on a “ superb “ drug for prostrate, lol !! PM Where MILLIONS are being spent at $KYMR PM to own a PHASE 1 company , hahaha, no Phase 2 or 3 GUESS TAK has credibility issues !!! And gets only 2800 out of the MILLIONS , Funds are spending ..BUT NOT ON HIM !!!! Hahah
0 · Reply
TalkMarkets
TalkMarkets Jun. 4 at 8:40 AM
Analyst Moves: 2 Upgrades And 1 Neutral Rating $PINS $KYMR $ASML https://talkmarkets.com/content/stocks--equities/analyst-moves-2-upgrades-and-1-neutral-rating?post=501170&userid=166882
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 4 at 6:59 AM
$KYMR congratulations on your recent phase 1 success! Is KT-621 truly the oral Dupixent? 💊 If so I may need to start buying shares once $TNXP $NUVB $ALT skyrocket soon 💎 ⛅️ 🚀 Hmm… 🤔 ~The Bonesaw of Biotech
0 · Reply
frogoracletrading
frogoracletrading Jun. 4 at 2:07 AM
$KYMR Support / Resistance Levels After hitting the 49.08 resistance level today KYMR has come back under 44.34. Needs to hold 42.32 to retest 45.97 to the upside. Larger Image: https://s3.tradingview.com/snapshots/b/BISrDXB3.png
0 · Reply
mikesterz7
mikesterz7 Jun. 4 at 1:56 AM
$KYMR Morgan Stanley maintained a Hold rating on Kymera Therapeutics, Inc. with a price target of $49.
0 · Reply
Wrangler4
Wrangler4 Jun. 4 at 1:27 AM
$KYMR Haha…hey misfits at $AGIO… This company with no submissions for years , and years Gets more analysts on board and follow thru on their value, than you clowns with a drug on the market and a submission pending You agio clowns are the laughing stock !! BUFFOONS
0 · Reply
Wrangler4
Wrangler4 Jun. 4 at 1:07 AM
$KYMR Been to $60 and fell apart …it was a dilution deal
0 · Reply
Wrangler4
Wrangler4 Jun. 4 at 1:05 AM
$KYMR how can it at phase 1 , lol You were all conned
0 · Reply
PinTheInvestor
PinTheInvestor Jun. 3 at 6:14 PM
Well, I got my gap fill on $KYMR after all. Now fully loaded, trusting that this investment lives up to its promise!
0 · Reply
anachartanalyst
anachartanalyst Jun. 3 at 5:02 PM
$KYMR https://anachart.com/wp-content/uploads/ana_temp/1748970119_soc-img.jpg
0 · Reply
ZacksResearch
ZacksResearch Jun. 3 at 4:43 PM
$KYMR surges on promising phase I results for KT-621! 🚀 The study showed KT-621's efficacy rivaling Dupixent with greater than 90% STAT6 degradation in blood and complete degradation in blood and skin for MAD doses over 50 mg. Plus, it's well-tolerated without severe adverse effects. Discover the full potential of KT-621 here 👉 https://www.zacks.com/commentary/2483703/kymera-stock-gains-on-positive-data-on-investigational-dermatitis-drug?cid=sm-stocktwits-2-2483703-body&ADID=SYND_STOCKTWITS_TWEET_2_2483703_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 3 at 3:38 PM
$KYMR pops on KT-621 data — is this a real Dupixent challenger? Phase I results beat expectations, with biomarker performance matching or topping Dupixent in Th2 diseases. Find out what could drive KYMR’s next breakout 👉 https://www.zacks.com/stock/news/2483703/kymera-stock-gains-on-positive-data-on-investigational-dermatitis-drug?cid=sm-stocktwits-2-2483703-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2483703_TEASER
0 · Reply
MaverikIT
MaverikIT Jun. 3 at 3:33 PM
0 · Reply
PinTheInvestor
PinTheInvestor Jun. 3 at 2:32 PM
Not hyping, just informing: $KYMR had similar stellar clinical results and will be trading like $SPRO has been for the last couple of days. In some overnight around 44, and then again this morning at 47 for traders.
0 · Reply